Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methotrexate transdermal drug delivery local controlled release preparation and preparation method and application thereof

A technology of methotrexate and controlled-release preparations, which is applied in the directions of pharmaceutical formulations, antipyretics, anti-inflammatory agents, etc., can solve the problems of reducing the dosage of drugs for patients, adverse reactions of patients, etc. High volume and loading rate, good biocompatibility

Active Publication Date: 2019-07-09
BEIJING UNIV OF AGRI
View PDF10 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The problem to be solved by the present invention is that the content of methotrexate preparations is reduced due to light and the generation of analogues, and the adverse reactions of patients caused by long-term large-scale administration can effectively reduce the dosage of patients.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methotrexate transdermal drug delivery local controlled release preparation and preparation method and application thereof
  • Methotrexate transdermal drug delivery local controlled release preparation and preparation method and application thereof
  • Methotrexate transdermal drug delivery local controlled release preparation and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] The preparation of embodiment 1 mesoporous silica

[0048]Add 24mL of cetyltrimethylammonium chloride (CTAC), 36mL of water, and 0.18g of triethanolamine (TEA) into a 100mL flask in sequence, and stir magnetically at a constant temperature of 80°C for 1h. The prepared mixture of 4 mL tetraethyl orthosilicate (TEOS) and 1 mL cycloethane was added dropwise and stirred slowly at 60° C. for 12 h. After the reaction is completed, wash with 0.6% ammonium nitrate ethanol solution three times in a 60° C. water bath, each time for 6 hours. After the reaction was completed, the ammonium nitrate was removed with absolute ethanol, and freeze-dried to obtain mesoporous silica. Characterization diagram of mesoporous silica Figure 1a and Figure 1b , Figure 1c , Figure 1d .

Embodiment 2

[0049] Embodiment 2. Methotrexate content assay method

[0050] (1) Chromatographic conditions

[0051] Use Shimadzu LC-6AD to detect methotrexate content, chromatographic column: Thermo ODS-2 C18 (150mm×4.6mm, 5μm), mobile phase is acetonitrile: water=17:83 (0.1% trifluoroacetic acid), detection Wavelength: 302nm, flow rate: 1ml / min, injection volume 20μl. Chromatographic column: SinoPak C18 5 μm. Column size: 4.6mm*200mm.

[0052] (2) Draw a standard curve

[0053] Dilute the previously prepared 110μg / ml MTX standard solution with distilled water to make solutions of 2.2μg / ml, 5.5μg / ml, 11μg / ml, 22μg / ml, 55μg / ml and 110μg / ml respectively, each concentration Inject once, each injection volume is 20 μl. Take the peak area as the ordinate, and the concentration of the standard solution as the abscissa, and perform linear regression.

[0054] (3) Sample processing method

[0055] Measure different concentrations of methotrexate with high performance liquid chromatography,...

Embodiment 3

[0056] Example 3. Stability study of methotrexate

[0057] The effects of light time, different pH values ​​(5.5, 7.4, 8.5, 9.0), and temperature (25°C, 40°C, 80°C) on the stability of methotrexate were compared.

[0058] (1) Light stability: Take 6 small centrifuge tubes, mark them, and add 1ml of each (110μg / ml, pH7.4) methotrexate solution into them with a pipette gun, and wrap the dark group completely with tinfoil To avoid light conditions. The two groups were placed under sunlight at the same time, and samples were taken at 6h, 24h, 48h, 96h, and 144h respectively.

[0059] (2) Temperature stability: Take 9 small centrifuge tubes, add 1ml of each (110μg / ml, pH 7.4) methotrexate solution into them with a pipette gun after marking, and store them in different temperatures (25°C) in the dark. , 40°C, 80°C), and samples were taken at 6h, 24h, 48h, 72h, and 96h.

[0060] (3) pH stability: Take 12 small centrifuge tubes, add pre-prepared methotrexate solutions with differen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pore sizeaaaaaaaaaa
diffusion coefficientaaaaaaaaaa
surface areaaaaaaaaaaa
Login to View More

Abstract

The invention discloses a methotrexate transdermal drug delivery local controlled release preparation and a preparation method and application thereof. The preparation is obtained through the steps that mesoporous silica is loaded with methotrexate, the surface is wrapped with a layer of polydopamine or polymethyldopa. The adopted mesoporous silica is good in biocompatibility, large in specific surface area and high in drug loading capacity, and is polymerized through polydopamine under alkaline conditions, and methotrexate is degraded and released under acidic conditions, and controlled drugrelease is achieved. The outer surface of a drug is wrapped with a layer of black polydopamine, the photostability of the methotrexate can be ensured, and better convenience is brought to the processof drug preservation and management. Meanwhile, it is found through research that polymethyldopa shows the similar gating effect as that of the polydopamine, and intelligent drug delivery is achieved.

Description

technical field [0001] The invention relates to the field of drug controlled release, in particular to a methotrexate transdermal local controlled release preparation and its preparation method and application, using mesoporous silicon dioxide to load methotrexate, polydopamine or methyldopa After encapsulation, the light stability of methotrexate is improved to realize the controllable release of methotrexate. Background technique [0002] Rheumatoid arthritis (RA) is an autoimmune disease mainly characterized by joint synovial inflammation and involving the whole body. Methotrexate (MTX), as the core drug of choice for the treatment of rheumatoid arthritis, can regulate the abnormal immunity of patients, significantly reduce cartilage destruction and bone erosion, control the aggravation of bone lesions, prevent or delay joint destruction, and reduce disability. It plays an important role in the treatment of controlling the progression of the disease. However, long-term ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/69A61K47/59A61K31/519A61P19/02A61P29/00A61P35/00
CPCA61K31/519A61K47/6923A61K47/59A61K9/0014A61P19/02A61P29/00A61P35/00
Inventor 常明明郭婷婷康旭
Owner BEIJING UNIV OF AGRI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com